Hepatology International

Home
India
New Delhi
Hepatology International

Official Journal of Asian Pacific Association for the Study of the Liver dedicated to research and patient care issues.

Account is owned and managed by the society and not by Springer Nature. Hepatology International is a peer-reviewed journal dedicated to research and patient care issues in hepatology. Focuses on contemporary clinical and basic science related issues in adult and pediatric hepatobiliary and allied sciences. Publishes original research articles, editorials, reviews, and consensus guidelines for dia

gnosis and treatment of liver diseases. Emphasizes on new and emerging technologies, innovations and future trends in liver and biliary disorders.

11/04/2026

Explore the role of liver stiffness measurement (LSM) in the noninvasive risk stratification of liver nodule development in patients with Fontan-associated liver disease (FALD).

This study provides important insights into early risk identification and surveillance strategies, supporting improved clinical decision-making in this complex patient population.

🔗 Read the full article: https://link.springer.com/article/10.1007/s12072-026-11087-3

31/03/2026

📢 Join us at APASL STC Singapore 2026 🇸🇬

📅 9–12 July 2026
📍 Singapore

Returning to Singapore—the birthplace of APASL, this meeting holds special significance as it brings the hepatology community back to where the vision for regional collaboration first began.

With a strong focus on cirrhosis, a major cause of morbidity and mortality across the Asia-Pacific region, the conference will explore aetiology-specific approaches to prevention, diagnosis, and management, reflecting the latest scientific advances and evolving clinical practice.

The scientific program will feature international and regional experts, delivering state-of-the-art lectures, interactive case-based discussions, and multidisciplinary sessions spanning viral hepatitis, MASLD, alcohol-related liver disease, autoimmune and cholestatic liver diseases, and more. Emphasis will be placed on personalized, evidence-based strategies to optimize patient outcomes.

APASL STC 2026 offers a unique platform for clinicians, researchers, trainees, and allied health professionals to exchange knowledge and advance cirrhosis care across diverse healthcare settings.

🔗 For more information and registration:
https://themeetinglab.eventsair.com/apasl-stc-2026

30/03/2026

Discover insights from a GRAFT trial sub-study evaluating immune biomarkers that predict response to G-CSF therapy in acute-on-chronic liver failure (ACLF).

This study advances understanding of patient stratification and highlights the potential of biomarker-driven approaches to optimize therapeutic outcomes in ACLF.

🔗 Read the full article: https://link.springer.com/article/10.1007/s12072-026-11069-5

25/03/2026

Explore the Australian best practice recommendations for transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension, presented as a comprehensive consensus statement.

This article provides evidence-based guidance on patient selection, procedural considerations, and post-TIPS management, supporting optimized clinical decision-making and improved patient outcomes.

🔗 Read the full article: https://link.springer.com/article/10.1007/s12072-025-11023-x

10/03/2026

Join leading experts and researchers at APASL Oncology 2026, focused on “Treatment Dynamics of Liver Tumors.” This specialized meeting will bring together the hepatology and oncology communities to discuss the latest advances in liver cancer research, treatment strategies, and multidisciplinary care.

📅 Dates: April 2–3, 2026
📍 Venue: Ito International Research Center, The University of Tokyo, Japan

Under the leadership of Chairman Dr. Shuntaro Obi, the meeting will provide an important platform for knowledge exchange and collaboration in liver oncology.

🔗 For more information and registration:
https://www.apasl-oncology2026tokyo.org

22/02/2026

Explore the findings of the ANCHOR randomized controlled trial, evaluating the efficacy and safety of combination therapy with entecavir, peginterferon alfa-2b, and GM-CSF in the management of chronic hepatitis B.

This rigorously conducted study provides important clinical insights into combination therapeutic strategies aimed at enhancing antiviral response and improving patient outcomes.

🔗 Read the full article: https://link.springer.com/article/10.1007/s12072-025-10977-2

01/01/2026

Warm New Year Greetings from Hepatology International

As we welcome the New Year, we extend our sincere gratitude to our authors, reviewers, editorial board members, and the global hepatology community for your continued trust and support.

May the year ahead bring renewed hope, scientific advancement, and meaningful collaboration as we work together to advance liver research and improve patient care worldwide.

We wish you a healthy, successful, and fulfilling New Year.

Hepatology International
Official Journal of the Asian Pacific Association for the Study of the Liver (APASL)

26/12/2025

Read the findings from the ANCHOR randomized controlled trial, evaluating the efficacy and safety of combination therapy with entecavir, peginterferon alfa-2b, and GM-CSF. This important study provides robust clinical evidence on combination treatment strategies aimed at improving outcomes in chronic hepatitis B management.

🔗 Read the full article: https://link.springer.com/article/10.1007/s12072-025-10977-2

24/11/2025

Explore new insights into the relationship between hepatic immune-related adverse events (irAEs) and patient outcomes in cancer therapy. This study reveals that the development of hepatic irAEs is associated with improved overall survival in patients with malignancies treated with immune checkpoint inhibitors, offering valuable implications for clinical management and monitoring.

🔗 Read the full article: https://link.springer.com/article/10.1007/s12072-025-10825-3

22/11/2025

Join us at APASL STC Pakistan 2025! 🇵🇰
📅 5–7 December 2025
📍 Karachi, Pakistan

Centered on the theme “MAFLD and Metabolic Complications: Applying Multidisciplinary Solutions,” this landmark conference unites leading experts across hepatology, endocrinology, cardiometabolic medicine, internal medicine, family medicine, nephrology, oncology, nutrition, and bariatric care.

The scientific program delves into the evolving landscape of metabolic liver disease, with sessions covering epidemiology, systemic complications, diagnostic pathways, non-invasive tools, incretin-based and emerging therapies, precision medicine, post-transplant considerations, and digital health applications — all tailored to LMIC contexts.

🔗 For more information and registration: www.apaslstc2025pakistan.com

Address

D-1, Vasant Kunj
New Delhi

Website

https://link.springer.com/journal/12072

Alerts

Be the first to know and let us send you an email when Hepatology International posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your business to be the top-listed Health & Beauty Business in New Delhi?